Brief: Shenzhen Neptunus Interlong Bio-Technique's Unit Enters Into JV Agreement With Huikang Bio-Technology
14/09/2026 11:37
BRIEF-Shenzhen Neptunus Interlong Bio-Technique's Unit Enters Into JV Agreement With Huikang Bio-Technology Sept 14 (Reuters) - Shenzhen Neptunus Interlong Bio-technique Co Ltd 8329.HK:
UNIT ENTERED INTO JOINT VENTURE AGREEMENT WITH HUIKANG BIO- TECHNOLOGY
JOINT VENTURE REGISTERED CAPITAL RMB5 MILLION
JOINT VENTURE TO SPECIALIZE IN EARLY CANCER SCREENING AND IN VITRO DIAGNOSTICS
Further company coverage: 8329.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shenzhen Neptunus Interlong Bio-technique
See all newsBrief: Shenzhen Neptunus Interlong Bio-Technique's Unit Enters Into JV Agreement With Huikang Bio-Technology
China's Neptunus Interlong H1 revenue falls
Brief: Shenzhen Neptunus Interlong Bio-Technique Expects Net Profit Attributable To Owners Of RMB 7 Million For 2026 Interim Period
Brief: Shenzhen Neptunus Interlong Bio-Technique Posts FY Loss & Total Comprehensive Expenses Attributable RMB40.7 Million
Brief: Shenzhen Neptunus Interlong Bio-Technique Sees FY Net Loss Attributable Of RMB40 Million